The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Okay, okay. Yes, just making sure. Okay. Sorry for the interruptions. Okay. Let me begin with asking you briefly to introduce the company, its vision,
how far have you all come since the inception and what makes Alector exciting?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 24, 2023 / 3:00PM, ALEC.OQ - H.C. Wainwright with Alector
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Great. So let's talk about AL001 or latozinemab and the FTD program. With now several companies targeting progranulin in what way Alector is
differentiated from other programs?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Great. So how has the biology been proven so far through your INFRONT trial?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Great. Let's talk about the biomarker data from INFRONT-2, be progranulin or NfL, or most importantly, GFAP, it indicates that AL001 robustly hits
the target. Given the regulatory environment, how confident are you with the data so far and how (inaudible) surrounding the biomarker (inaudible)?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Got it. Great. So just following up on the previous question. Within the recent approvals in (inaudible), the role of natural history data has come to
prominence. Where do you see the value of GENFI data set compared to other disease natural history data and how its GENFI dataset or any
(inaudible) with the FTD program?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Got it. Very nice. Let's shift gear to the C9orf72 trial. Can you briefly explain the rationale behind the trial and what makes the preliminary data
exciting as it mirrors some of the data from the INFRONT-2?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Got it. Let's now move to the TREM2 program. You are one of the pioneers in bringing TREM2 activating antibody to the clinic. What was the
rationale behind choosing the target and the indication?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Great. So from the time you started the TREM2 program, the landscape of AD immunotherapy has dramatically changed, as we know. So how do
you see the development surrounding the anti-amyloids with respect to your TREM2 program? And how and where does TREM2 fit in the landscape?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 24, 2023 / 3:00PM, ALEC.OQ - H.C. Wainwright with Alector
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Right. And you mentioned about ARIA, what's your thought about ARIA?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Very nice. So what is the data that might be most important for Alector, so that which might be the decision point where you decide that the drug
is ready to move to the Phase III program?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Got it. And let's talk briefly about your -- like the way -- it's still early, but still, I think it will help the community to understand. Like how different
or similar might is 002 Phase III design be from other Abeta immunotherapies, especially in the context of -- with the current Abeta amyloid, it looks
like that they have figured out a way to perfect the trial design.
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Sure.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 24, 2023 / 3:00PM, ALEC.OQ - H.C. Wainwright with Alector
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Got it. Let's delve a little bit on the ARIA, barring a few cases of ARIA in the ApoE4 homozygous patients, the trial has so far gone quite smoothly.
So what has been your take on ARIA-E concerning the TREM2 program as you were thinking through Phase II, Phase III or beyond?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Correct. Very helpful. So that kind of brings us to the last question for this webinar. Where do you see Alector in the next 5 years?
Question: Ananda Kumar Ghosh - H.C. Wainwright & Co, LLC, Research Division - Analyst
: Very nice. I think with that, we kind of come to the end of the fireside chat, I think it was very helpful for the investment community in general and
for ourselves also to get a broad insight on what to expect as -- in the next 2 years in the Alector. Thanks so much.
| 
